173 related articles for article (PubMed ID: 34344784)
1. OLGIM staging and proton pump inhibitor use predict the risk of gastric cancer.
Arai J; Niikura R; Hayakawa Y; Aoki T; Yamada A; Kawai T; Fujishiro M
Gut; 2022 May; 71(5):1043-1044. PubMed ID: 34344784
[No Abstract] [Full Text] [Related]
2. Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for
Niikura R; Hayakawa Y; Hirata Y; Yamada A; Fujishiro M; Koike K
Gut; 2018 Oct; 67(10):1908-1910. PubMed ID: 29273641
[No Abstract] [Full Text] [Related]
3. Proton pump inhibitors and gastric cancer: a population-based cohort study.
Patel J; Berezowski I; Janapala RN; Pourmand A
Gut; 2022 May; 71(5):1039-1041. PubMed ID: 34261754
[No Abstract] [Full Text] [Related]
4. Haemorrhagic gastric hyperplastic polyps associated with long-term use of proton pump inhibitor in a case without Helicobacter pylori infection.
Kinoshita S; Nishizawa T; Mori H; Kikuchi M
J Clin Pharm Ther; 2019 Jun; 44(3):493. PubMed ID: 30773665
[No Abstract] [Full Text] [Related]
5. Comparison of operative link for gastritis assessment, operative link on gastric intestinal metaplasia assessment, and TAIM stagings among men with atrophic gastritis.
Nieminen AA; Kontto J; Puolakkainen P; Virtamo J; Kokkola A
World J Gastroenterol; 2020 Jun; 26(24):3447-3457. PubMed ID: 32655268
[TBL] [Abstract][Full Text] [Related]
6. [Helicobacter pylori gastritis: assessment of OLGA and OLGIM staging systems].
Ben Slama S; Ben Ghachem D; Dhaoui A; Jomni MT; Dougui MH; Bellil K
Pan Afr Med J; 2016; 23():28. PubMed ID: 27200133
[TBL] [Abstract][Full Text] [Related]
7. OLGA and OLGIM stage distribution according to age and Helicobacter pylori status in the Korean population.
Nam JH; Choi IJ; Kook MC; Lee JY; Cho SJ; Nam SY; Kim CG
Helicobacter; 2014 Apr; 19(2):81-9. PubMed ID: 24617667
[TBL] [Abstract][Full Text] [Related]
8. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori.
Hagiwara T; Mukaisho K; Nakayama T; Sugihara H; Hattori T
Gut; 2011 May; 60(5):624-30. PubMed ID: 21097844
[TBL] [Abstract][Full Text] [Related]
9. Long-term proton pump inhibitor use after
Kobayashi J; Uchida H; Ito J
Gut; 2019 Jun; 68(6):1131. PubMed ID: 29802173
[No Abstract] [Full Text] [Related]
10. Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes.
Nasser SC; Slim M; Nassif JG; Nasser SM
World J Gastroenterol; 2015 Apr; 21(15):4599-606. PubMed ID: 25914469
[TBL] [Abstract][Full Text] [Related]
11. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.
Laine L; Ahnen D; McClain C; Solcia E; Walsh JH
Aliment Pharmacol Ther; 2000 Jun; 14(6):651-68. PubMed ID: 10848649
[TBL] [Abstract][Full Text] [Related]
12.
Suzuki H; Matsuzaki J
Gut; 2018 Nov; 67(11):2071-2072. PubMed ID: 29247066
[No Abstract] [Full Text] [Related]
13. HELICOBACTER PYLORI CHRONIC GASTRITIS ON PATIENTS WITH PREMALIGNANT CONDITIONS: OLGA AND OLGIM EVALUATION AND SERUM BIOMARKERS PERFORMANCE.
Coelho MCF; Ribeiro HG; Gomes CGO; Marinho FP; Barbosa AJA; Coelho LGV
Arq Gastroenterol; 2021; 58(1):39-47. PubMed ID: 33909795
[TBL] [Abstract][Full Text] [Related]
14. Gastric Hyperplastic Polyps Associated with Proton Pump Inhibitor Use in a Case without a History of Helicobacter pylori Infection.
Miyamoto S; Kato M; Matsuda K; Abiko S; Tsuda M; Mizushima T; Yamamoto K; Ono S; Kudo T; Shimizu Y; Hatanaka KC; Tsunematsu I; Sakamoto N
Intern Med; 2017; 56(14):1825-1829. PubMed ID: 28717077
[TBL] [Abstract][Full Text] [Related]
15. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for
Cheung KS; Chan EW; Wong AYS; Chen L; Wong ICK; Leung WK
Gut; 2018 Jan; 67(1):28-35. PubMed ID: 29089382
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitor therapy after
Tan MC; Graham DY
BMJ Evid Based Med; 2018 Jun; 23(3):111-112. PubMed ID: 29599181
[No Abstract] [Full Text] [Related]
17. Rationale for a Helicobacter pylori Test and Treatment Strategy in Gastroesophageal Reflux Disease.
Vakil N
Gastroenterol Clin North Am; 2015 Sep; 44(3):661-6. PubMed ID: 26314675
[TBL] [Abstract][Full Text] [Related]
18. High-risk individuals for gastric cancer would be missed for surveillance without subtyping of intestinal metaplasia.
Isajevs S; Savcenko S; Liepniece-Karele I; Piazuelo MB; Kikuste I; Tolmanis I; Vanags A; Gulbe I; Mezmale L; Samentaev D; Tazedinov A; Samsutdinov R; Belihina T; Igissinov N; Leja M
Virchows Arch; 2021 Oct; 479(4):679-686. PubMed ID: 33990867
[TBL] [Abstract][Full Text] [Related]
19. The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China.
Wang X; Lu B; Meng L; Fan Y; Zhang S; Li M
Scand J Gastroenterol; 2017 Aug; 52(8):822-827. PubMed ID: 28436254
[TBL] [Abstract][Full Text] [Related]
20. The corpus-predominant gastritis index may serve as an early marker of Helicobacter pylori-infected patients at risk of gastric cancer.
Tsai YC; Hsiao WH; Yang HB; Cheng HC; Chang WL; Lu CC; Sheu BS
Aliment Pharmacol Ther; 2013 May; 37(10):969-78. PubMed ID: 23550594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
